Physician

Adam Faye

According to 2025 Medicare claims, Adam Faye (NPI: 1538401005) practices gastroenterology in the New York-Jersey City-White Plains, NY-NJ market, with the plurality of this provider's patient population coming from New York, NY. This provider's primary affiliated billing organization is NEW YORK UNIVERSITY (NPI: 1285826438; TIN: 472665045) and primary practice location at 10016-6402. Faye is affiliated with the NewYork Quality Care (ACO ID: A2571) and NPG Health Collaborative LLC (ACO ID: A3287), participating under the MSSP model.

Faye's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 35 traditional Medicare patients, billed 110 HCPCS/CPT codes, and received $8,407 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 66 prescription claims across 18 beneficiaries totaling $474,527 in drug costs, led by Stelara (Ustekinumab). Open Payments data shows 49 records totaling $35,120. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have risen steadily, from $42,474 to $474,527. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$6.2K$12K2017 Medicare payment: $5,306 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $10,596 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $10,471 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $12,319 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $8,407 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
2015N/RN/RN/R
2016N/RN/RN/R
20173190$5,306
2018N/RN/RN/R
2019N/RN/RN/R
2020N/RN/RN/R
202150101$10,596
202249100$10,471
202367126$12,319
202435110$8,407

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$313K$626K2015 Drug cost: $42,474 (USD; Tot_Drug_Cst)2016 Drug cost: $57,372 (USD; Tot_Drug_Cst)2017 Drug cost: $29,341 (USD; Tot_Drug_Cst)2018 Drug cost: $114,335 (USD; Tot_Drug_Cst)2019 Drug cost: $288,915 (USD; Tot_Drug_Cst)2020 Drug cost: $225,569 (USD; Tot_Drug_Cst)2021 Drug cost: $342,853 (USD; Tot_Drug_Cst)2022 Drug cost: $5,301 (USD; Tot_Drug_Cst)2023 Drug cost: $625,851 (USD; Tot_Drug_Cst)2024 Drug cost: $474,527 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
201561690$42,474
201645873$57,372
201736451$29,341
201847148$114,335
201929127$288,915
202047166$225,569
202130103$342,853
20221527$5,301
20231344$625,851
20241866$474,527

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
99215Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more1117$107

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
StelaraUstekinumab13364$362,444
MesalamineMesalamine11810$3,451

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.49$35,120Takeda Pharmaceuticals U.S.A., Inc.
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Adam Faye?

Tedicare shows public-source Medicare data for Adam Faye (NPI 1538401005), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Adam Faye have ACO affiliation data?

Adam Faye is shown with ACO affiliation data for NewYork Quality Care (MSSP, ACO ID A2571) and NPG Health Collaborative LLC (MSSP, ACO ID A3287).

What billing organization is linked to Adam Faye?

Adam Faye is linked to NEW YORK UNIVERSITY (billing NPI 1285826438) in the available physician profile data.

Does Adam Faye have Open Payments data?

Adam Faye has 49 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.